Loading...

Merus

DB:2GH
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2GH
DB
$367M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Merus has significant price volatility in the past 3 months.
2GH Share Price and Events
7 Day Returns
11.1%
DB:2GH
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:2GH
-10.2%
DE Biotechs
-6%
DE Market
2GH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Merus (2GH) 11.1% 35% 36.1% - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 2GH.
  • No trading data on 2GH.
Price Volatility
2GH
Industry
5yr Volatility vs Market
Related Companies

2GH Value

 Is Merus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Merus. This is due to cash flow or dividend data being unavailable. The share price is €15.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Merus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Merus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2GH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.09
NasdaqGM:MRUS Share Price ** NasdaqGM (2019-04-18) in USD $15.7
NasdaqGM:MRUS Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.889 €13.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Merus.

DB:2GH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MRUS Share Price ÷ EPS (both in EUR)

= 13.96 ÷ -1.09

-12.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merus is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Merus is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Merus's expected growth come at a high price?
Raw Data
DB:2GH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-7.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Merus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Merus's assets?
Raw Data
DB:2GH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €3.93
NasdaqGM:MRUS Share Price * NasdaqGM (2019-04-18) in USD $15.7
NasdaqGM:MRUS Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.889 €13.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2GH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MRUS Share Price ÷ Book Value per Share (both in EUR)

= 13.96 ÷ 3.93

3.55x

* Primary Listing of Merus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Merus is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Merus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Merus has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2GH Future Performance

 How is Merus expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Merus expected to grow at an attractive rate?
  • Unable to compare Merus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Merus's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Merus's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2GH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2GH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -7.2%
DB:2GH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 38.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2GH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2GH Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 180 -56 4
2022-12-31 80 -80 4
2021-12-31 50 -52 -94 4
2020-12-31 36 -53 -79 5
2019-12-31 28 -54 -65 2
DB:2GH Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 31 -40 -24
2018-09-30 29 -40 -36
2018-06-30 20 -37 -47
2018-03-31 20 -44 -62
2017-12-31 22 -37 -65
2017-09-30 15 -37 -85
2017-06-30 11 -29 -76
2017-03-31 6 -26 -61
2016-12-31 3 -26 -47
2016-09-30 4 -24 -22
2016-06-30 3 -27 -23
2016-03-31 3 -25 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Merus is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Merus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2GH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Merus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2GH Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.12 -2.04 -2.20 2.00
2022-12-31 -2.80 -2.68 -2.92 2.00
2021-12-31 -2.90 -1.86 -3.43 3.00
2020-12-31 -2.75 -2.06 -3.11 3.00
2019-12-31 -2.70 -2.63 -2.78 2.00
DB:2GH Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.09
2018-09-30 -1.67
2018-06-30 -2.27
2018-03-31 -3.12
2017-12-31 -3.37
2017-09-30 -4.63
2017-06-30 -4.34
2017-03-31 -3.91
2016-12-31 -3.58
2016-09-30 -1.93
2016-06-30 -2.59
2016-03-31 -3.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Merus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Merus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Merus has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2GH Past Performance

  How has Merus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Merus's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Merus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Merus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Merus's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Merus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Merus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2GH Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 31.45 -24.27 10.87
2018-09-30 29.05 -35.71 10.93
2018-06-30 19.94 -46.79 12.00
2018-03-31 19.64 -61.80 13.01
2017-12-31 21.92 -64.77 14.33
2017-09-30 15.23 -84.94 15.15
2017-06-30 10.90 -76.22 11.81
2017-03-31 5.76 -61.49 8.60
2016-12-31 2.51 -47.44 4.83
2016-09-30 3.50 -21.93 1.93
2016-06-30 2.66 -23.12 1.44
2016-03-31 2.72 -23.81 1.09
2015-12-31 1.91 -23.26 0.94
2015-09-30 2.15 -22.29 0.55
2015-06-30 2.23 -20.75 -0.64
2015-03-31 1.24 -18.71 -0.02
2014-12-31 1.30 -17.41 0.55
2013-12-31 0.56 -9.91 2.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Merus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Merus has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Merus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Merus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Merus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2GH Health

 How is Merus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Merus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Merus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Merus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Merus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Merus has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Merus Company Filings, last reported 3 months ago.

DB:2GH Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 91.87 0.00 188.60
2018-09-30 84.93 0.00 193.10
2018-06-30 92.87 0.00 207.40
2018-03-31 95.37 0.00 204.36
2017-12-31 56.59 0.00 183.72
2017-09-30 59.75 0.00 202.42
2017-06-30 72.76 0.00 215.79
2017-03-31 91.28 0.00 236.51
2016-12-31 34.42 0.49 56.92
2016-09-30 63.74 0.54 66.27
2016-06-30 68.36 0.58 71.15
2016-03-31 23.19 0.63 26.15
2015-12-31 28.30 0.65 32.85
2015-09-30 34.14 0.71 40.10
2015-06-30 -8.40 8.34 6.57
2015-03-31 -3.56 0.82 1.57
2014-12-31 -3.56 0.82 1.57
2013-12-31 7.66 0.99 10.65
  • Merus has no debt.
  • Merus has no debt compared to 5 years ago when it was 12.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Merus has sufficient cash runway for more than 3 years based on current free cash flow.
  • Merus has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 23% each year.
X
Financial health checks
We assess Merus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Merus has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2GH Dividends

 What is Merus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Merus dividends. Estimated to be 0% next year.
If you bought €2,000 of Merus shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Merus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Merus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2GH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2GH Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Merus has not reported any payouts.
  • Unable to verify if Merus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Merus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Merus has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Merus's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Merus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Merus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Merus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2GH Management

 What is the CEO of Merus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ton Logtenberg
COMPENSATION €21,991,380
AGE 60
TENURE AS CEO 15.8 years
CEO Bio

Dr. Ton Logtenberg, Ph.D. has been Principal Financial Officer of Merus N.V. since January 2019. Dr. Logtenberg serves as President, Chief Executive Officer and Director of Merus N.V. since June 2003. Dr. Logtenberg serves as President of the subsidiary, Merus US, Inc. Dr. Logtenberg co-founded Crucell N.V. and served as its Executive Vice President and Chief Scientific Officer from July 2000 to November 2003. served as its External Advisor and Member of Management Board. He Co-founded U-BiSys and served as its General Manager and Chief Scientific Officer. Dr. Logtenberg served at the U-BiSys Management Board in June 2000, in connection with the merger between IntroGene and U-BiSys. From 1994 to 1995 he served as a Visiting Scientist at Becton Dickinson Immunocytometry Systems. He is a Professor of immuno-biotechnology at the University of Utrecht since 1996. Dr. Logtenberg is a part-time Professor and Staff Member of the Department of Immunology at the University Medical Center Utrecht. From 1989 to 1995 he was a Senior Researcher on a fellowship from the Royal Dutch Academy of Arts and Sciences. He has been an Executive Director of Merus B.V. since June 5, 2017. Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of Utrecht Science Park since November 2014. From 1987 to 1989, Dr. Logtenberg was a post-doctoral fellow at the Howard Hughes Institute, Department of Biochemistry at Columbia University in New York. Dr. Logtenberg has a Masters in Biology and a Ph.D. from the University of Utrecht.

CEO Compensation
  • Ton's compensation has increased whilst company is loss making.
  • Ton's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Merus management team in years:

4.8
Average Tenure
51
Average Age
  • The tenure for the Merus management team is about average.
Management Team

Ton Logtenberg

TITLE
President
COMPENSATION
€22M
AGE
60
TENURE
15.8 yrs

Hennie Hoogenboom

TITLE
Co-Founder and Scientific Advisor

Jillian Connell

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
0.6 yrs

John de Kruif

TITLE
CTO & Senior VP
AGE
54
TENURE
6.3 yrs

Mark Throsby

TITLE
Chief Scientific Officer & Executive VP
AGE
51
TENURE
6.3 yrs

Peter Silverman

TITLE
Executive VP
AGE
40
TENURE
1.2 yrs

Lex Bakker

TITLE
CDO & Senior VP
AGE
51

Hui Liu

TITLE
Chief Business Officer
AGE
51
TENURE
3.3 yrs

L. Sirulnik

TITLE
Chief Medical Officer & Executive VP
AGE
51
TENURE
2.5 yrs

Ellen Broug

TITLE
Executive Director of IP & Secretary
TENURE
8.9 yrs
Board of Directors Tenure

Average tenure and age of the Merus board of directors in years:

2.1
Average Tenure
58
Average Age
  • The average tenure for the Merus board of directors is less than 3 years, this suggests a new board.
Board of Directors

Russell Greig

TITLE
Chairman of the Board
AGE
66
TENURE
0.8 yrs

Ton Logtenberg

TITLE
President
COMPENSATION
€22M
AGE
60
TENURE
15.8 yrs

Mark Iwicki

TITLE
Non Executive Director
COMPENSATION
€181K
AGE
52
TENURE
3.8 yrs

Greg Perry

TITLE
Non-Executive Director
COMPENSATION
€151K
AGE
58
TENURE
2.9 yrs

John de Koning

TITLE
Non-Executive Director
COMPENSATION
€152K
AGE
49
TENURE
9.3 yrs

Elaine Jones

TITLE
Board Observer
AGE
63
TENURE
9.3 yrs

Anand Mehra

TITLE
Non-Executive Director
COMPENSATION
€126K
AGE
42
TENURE
1.3 yrs

Len Kanavy

TITLE
Non-Executive Director
AGE
56
TENURE
0.8 yrs

Hans Clevers

TITLE
Member of Scientific Advisory Board
AGE
61
TENURE
0.7 yrs

Toni Ribas

TITLE
Member of Scientific Advisory Board
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Jul 18 Sell Novo Holdings A/S Company 19. Jul 18 24. Jul 18 -307,622 €20.55 €-5,540,262
X
Management checks
We assess Merus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Merus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2GH News

Simply Wall St News

2GH Company Info

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Details
Name: Merus N.V.
2GH
Exchange: DB
Founded: 2003
$326,101,596
23,358,977
Website: http://www.merus.nl
Address: Merus N.V.
Yalelaan 62,
Utrecht,
Utrecht, 3584 CM,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MRUS Common Stock Nasdaq Global Market US USD 19. May 2016
DB 2GH Common Stock Deutsche Boerse AG DE EUR 19. May 2016
Number of employees
Current staff
Staff numbers
98
Merus employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:11
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/04/03
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.